Psyence Biomedical (PBM) Competitors $5.21 -0.11 (-2.07%) Closing price 03:56 PM EasternExtended Trading$5.30 +0.09 (+1.73%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. ACXP, BCDA, CSCI, CLDI, SNPX, PHXM, ADXN, GLYC, CYCN, and XFORShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Acurx Pharmaceuticals (ACXP), BioCardia (BCDA), COSCIENS Biopharma (CSCI), Calidi Biotherapeutics (CLDI), Synaptogenix (SNPX), PHAXIAM Therapeutics (PHXM), Addex Therapeutics (ADXN), GlycoMimetics (GLYC), Cyclerion Therapeutics (CYCN), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Its Competitors Acurx Pharmaceuticals BioCardia COSCIENS Biopharma Calidi Biotherapeutics Synaptogenix PHAXIAM Therapeutics Addex Therapeutics GlycoMimetics Cyclerion Therapeutics X4 Pharmaceuticals Acurx Pharmaceuticals (NASDAQ:ACXP) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts rate ACXP or PBM? Acurx Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 1,757.87%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Acurx Pharmaceuticals is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ACXP or PBM? In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.89 beat Acurx Pharmaceuticals' score of 0.94 indicating that Psyence Biomedical is being referred to more favorably in the news media. Company Overall Sentiment Acurx Pharmaceuticals Positive Psyence Biomedical Very Positive Is ACXP or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -526.78% -223.78% Psyence Biomedical N/A N/A N/A Which has more risk & volatility, ACXP or PBM? Acurx Pharmaceuticals has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Which has higher earnings & valuation, ACXP or PBM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.62Psyence BiomedicalN/AN/A$1.01MN/AN/A Do insiders & institutionals have more ownership in ACXP or PBM? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryPsyence Biomedical beats Acurx Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.97M$2.92B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.4928.6119.73Price / SalesN/A265.46412.00173.26Price / Cash3.0043.1536.0257.96Price / Book0.447.768.235.67Net Income$1.01M-$55.11M$3.23B$257.79M7 Day Performance6.33%0.95%-0.01%0.52%1 Month Performance19.50%8.44%5.61%8.84%1 Year Performance-98.01%-2.38%26.52%14.18% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence Biomedical0.9841 of 5 stars$5.21-2.1%N/A-97.5%$2.97MN/A0.00N/APositive NewsGap DownACXPAcurx Pharmaceuticals2.5666 of 5 stars$0.49+3.6%$8.00+1,537.7%-81.9%$11.07MN/A-0.703BCDABioCardia3.6076 of 5 stars$2.29+9.0%$25.00+991.7%-35.6%$10.87M$60K-0.9840News CoveragePositive NewsCSCICOSCIENS BiopharmaN/A$3.65+6.1%N/AN/A$10.82M$9.59M-0.6320CLDICalidi Biotherapeutics0.566 of 5 stars$0.34+39.5%N/A-67.1%$10.65MN/A0.0038Gap UpHigh Trading VolumeSNPXSynaptogenix0.3115 of 5 stars$7.63-10.2%$14.00+83.5%+130.2%$10.61MN/A-0.764Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ADXNAddex Therapeutics2.5142 of 5 stars$9.52+1.5%$30.00+215.1%+8.5%$10.05M$460K-28.0030Positive NewsGLYCGlycoMimetics0.5099 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading VolumeCYCNCyclerion Therapeutics2.5359 of 5 stars$3.14+1.6%N/A+8.9%$9.92M$2M-2.7130News CoveragePositive NewsXFORX4 Pharmaceuticals4.9221 of 5 stars$1.67-1.2%$72.33+4,244.3%-93.1%$9.75M$2.56M0.7880Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Acurx Pharmaceuticals Alternatives BioCardia Alternatives COSCIENS Biopharma Alternatives Calidi Biotherapeutics Alternatives Synaptogenix Alternatives PHAXIAM Therapeutics Alternatives Addex Therapeutics Alternatives GlycoMimetics Alternatives Cyclerion Therapeutics Alternatives X4 Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
